HONG KONG – After a prolonged negotiation process, China has secured drug prices that are, in some cases, much lower than those in Europe and other developed markets.
NEW DELHI – In what may end up as a landmark $1.3 billion deal, China’s Shanghai Fosun Pharmaceutical (Group) Ltd. is set to acquire Indian injectables specialist Gland Pharma Ltd.
NEW DELHI – In what may end up as a landmark $1.3 billion deal, China’s Shanghai Fosun Pharmaceutical (Group) Ltd. is set to acquire Indian injectables specialist Gland Pharma Ltd.
HONG KONG – A team of Chinese scientists from Sichuan University's West China Hospital in the city of Chengdu is one step closer to initiating the world's first human CRISPR clinical trial to test gene-editing technology in a lung cancer treatment.
HONG KONG – Japan's Chugai Pharmaceutical Co. Ltd. has licensed rights to its treatment for skin diseases to the company's Swiss partner, Galderma Pharma SA. The global agreement gives Lausanne-based Galderma rights to antibody nemolizumab, or CIM331. The drug is close to completing a global phase II study in the U.S., Japan and three European countries, for the treatment of atopic dermatitis.
HONG KONG – A team of Chinese scientists from Sichuan University's West China Hospital in the city of Chengdu is one step closer to initiating the world's first human CRISPR clinical trial to test gene-editing technology in a lung cancer treatment.
HONG KONG – Japan's Chugai Pharmaceutical Co. Ltd. has licensed rights to its treatment for skin diseases to the company's Swiss partner, Galderma Pharma SA. The global agreement gives Lausanne-based Galderma rights to antibody nemolizumab, or CIM331.
HONG KONG – A decade after the U.S. launch, Glaxosmithkline plc's (GSK) Cervarix vaccine to prevent the human papillomavirus (HPV) is in the home stretch to launch as the first HPV vaccine in Mainland China.
